S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

OncLive® On Air - Un pódcast de OncLive® On Air

prueba podimo gratis durante 60 días!

Miles de audiolibros y podcasts exclusivos, haz clic aquí para probar

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.